重组牛碱性成纤维细胞生长因子治疗角膜深层铁屑异物的有效性研究

Study on the effectiveness of recombinant bovine basic fibroblast growth factor in the treatment of deep corneal iron filings

目的探讨重组牛碱性成纤维细胞生长因子(商品名:贝复舒)治疗角膜深层铁屑异物的有效性。方法角膜深层铁屑异物患者100例(100眼),采用随机数字表法分为第一组(33例,33眼)、第二组(36例,36眼)和第三组(31例,31眼)。第一组仅用抗感染药物(托百士眼液)进行治疗,第二组应用托百士眼液联合重组牛碱性成纤维细胞生长因子眼液进行治疗,第三组应用托百士眼液联合白天重组牛碱性成纤维细胞生长因子眼液+中午及夜晚睡前重组牛碱性成纤维细胞生长因子眼凝胶治疗。在损伤后第2、4、7、10天复诊回访。比较三组临床疗效、角膜创面愈合时间、不良反应发生率。结果第三组临床治疗总有效率96.77%高于第一组的72.73%和第二组的77.78%,差异具有统计学意义(P<0.05)。第三组患者的角膜创面愈合时间为(5.34±0.21)d,明显短于第一组的(7.34±0.29)d与第二组的(7.08±0.23)d,差异均具有统计学意义(t=31.425、32.134,P=0.000、0.000<0.05)。第三组不良反应发生率3.23%低于第一组的30.30%和第二组的19.44%,且第二组低于第一组,差异均具有统计学意义(P<0.05)。结论重组牛碱性成纤维细胞生长因子在治疗角膜深层铁屑异物中具有较高的有效性,不仅能够有效的提升临床疗效,缩短角膜创面愈合时间,还能降低不良反应发生率。

Objective To discuss the effectiveness of recombinant bovine basic fibroblast growth factor(trade name:Beifushu)in the treatment of deep corneal iron filings.Methods A total of 100 cases(100 eyes)of patients with deep corneal iron filings were randomly divided into the first group(33 cases,33 eyes),the second group(36 cases,36 eyes)and the third group(31 cases,31 eyes)by random numerical table.The first group was treated with anti-infective drugs(Tobrex eye drops)only,and the second group was treated with Tobrex eye drops combined with recombinant bovine basic fibroblast growth factor eye drops,and the third group was treated with Tobrex eye drops combined with recombinant bovine basic fibroblast growth factor eye drops at daytime and recombinant bovine basic fibroblast growth factor gel at night before bedtime.Follow-up visits were made on the 2nd,4th,7th,and 10th days after the injury.The clinical efficacy,corneal wound healing time,and incidence of adverse reactions were compared among the three groups.Results The total effective rate of clinical treatment 96.77% in the third group was higher than 72.73% in the first group and 77.78% in the second group,and the difference was statistically significant(P<0.05).The corneal wound healing time of the third group was(5.34±0.21)d,which was significantly shorter than(7.34±0.29)d in the first group and(7.08±0.23)d in the second group,and the difference was statistically significant(t=31.425,32.134;P=0.000,0.000<0.05).The incidence of adverse reactions 3.23% in the third group was lower than 30.30% in the first group and 19.44% in the second group,and the second group was lower than the first group.All the differences were statistically significant(P<0.05).Conclusion Recombinant bovine basic fibroblast growth factor has high effectiveness in the treatment of deep corneal iron filings.It can not only effectively improve the clinical efficacy,shorten the healing time of corneal wounds,but also reduce the incidence of adverse reactions.